MedTrace Logo

Central Pain Study for ABX-1431

NCT03138421 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2019-01-25

No results posted yet for this study

Summary

This study will determine the safety and tolerability of ABX-1431 in patients with central pain when added on to background pain therapy.

During the course of this study, each participant will take a daily dose of 20 mg of ABX-1431 or a matching placebo for approximately 7 to 9 weeks.

Conditions

Interventions

DRUG

ABX-1431 HCl

ABX-1431 HCl, capsules, 20 mg

DRUG

Placebo

Matching placebo

Sponsors & Collaborators

  • Abide Therapeutics

    lead INDUSTRY

Principal Investigators

  • Jacqueline Palace, FRCP DM · Oxford University Hospitals NHS Trust

  • Anu Jacob, MD DM FRCP · The Walton Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2018-07-23
Completion
2018-07-24

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03138421 on ClinicalTrials.gov